Innovent Biologics (HKG:1801) recorded over 50% increase in profit in the first half of 2026 to 1.25 billion yuan from 834.3 million yuan a year prior, according to a Tuesday filing with the Hong Kong bourse.
Earnings per share climbed to 0.70 yuan from 0.49 yuan in the corresponding period of the last year.
Total revenue for the drug company jumped 44.8% to 8.62 billion yuan from 5.95 billion yuan in the year-ago period.